PDC-APB

PDC-APB
Clinical data
Other names	3-Pentadecyl-1,2-phenylene bis(4-(4-aminophenyl)butanoate; Benzenebutanoic acid, 4-amino-, 1,1'-(3-pentadecyl-1,2-phenylene) ester; UNII-LX6RQK5701
Identifiers
	IUPAC name [2-[4-(4-aminophenyl)butanoyloxy]-3-pentadecylphenyl] 4-(4-aminophenyl)butanoate;
CAS Number	2016046-95-8;
PubChem CID	89683272;
Chemical and physical data
Formula	C41H58N2O4
Molar mass	642.925 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCCCCCCCCCCCCCC1=C(C(=CC=C1)OC(=O)CCCC2=CC=C(C=C2)N)OC(=O)CCCC3=CC=C(C=C3)N;
	InChI InChI=1S/C41H58N2O4/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-20-35-21-17-22-38(46-39(44)23-15-18-33-25-29-36(42)30-26-33)41(35)47-40(45)24-16-19-34-27-31-37(43)32-28-34/h17,21-22,25-32H,2-16,18-20,23-24,42-43H2,1H3; Key:VLRZIRYGLUVGGU-UHFFFAOYSA-N;

PDC-APB, or 3-Pentadecyl-1,2-phenylene bis(4-(4-aminophenyl)butanoate)^[1] is a drug candidate under evaluation to determine if it might protect against contact dermatitis caused by urishiol from poison ivy, poison oak, and poison sumac.^[2]^[3]

History

The compound is one of a class of compounds developed through University of Mississippi research^[4] by Mahmoud ElSohly, Waseem Gul, and Mohammad Khalid Ashfaq.^[1] Work on the compound is ongoing under Hapten Sciences,^[5] who licensed the university's research in 2010.^[4]

The compound has been evaluated in two Phase I clinical trials, and a third Phase I randomized controlled trial, with a secondary objective of evaluating the effect of treatment on urishiol sensitivity, is due to be completed in December 2022.^[6]

^ ^a ^b US patent 10322103B2, "Compositions for prevention/prophylactic treatment of poison ivy dermatitis", issued 18 June 2019
^ Wallis, Claudia (1 September 2021). "A Vaccine against Poison Ivy Misery Is in the Works as Scientists Also Explore New Treatment Paths". Scientific American. doi:10.1038/scientificamerican0921-24. Retrieved 27 July 2022.
^ O'Laughlin, Frank (23 September 2021). "Report: Vaccine that guards against poison ivy misery in the works". WHDH TV. Retrieved 27 July 2022.
^ ^a ^b Stewart, Shea (18 June 2019). "University Obtains New Patent for Poison Ivy, Oak Vaccine Compound in clinical development with Memphis-based company". RedHillsMSNews.com. Winston County Journal. Retrieved 27 July 2022.
^ Jefferson, Ron (22 September 2021). "University of Mississippi and Hapten's Poison Ivy Vaccine Development Now in Clinical Trials". The Science Times. Retrieved 27 July 2022.
^ Doctor, Vanessa (22 September 2021). "A Prophylactic for Poison Ivy? Phase I Trial Set to Begin". BioSpace. Retrieved 27 July 2022.